1. Scrip
  2. >>Business
  3. >>Earnings

Lundbeck Ready To Funnel 2022 Growth Into Expected Alzheimer’s Agitation Launch

 
• By Joseph Haas

The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.

Lundbeck
Lundbeck is getting for an approval in Alzheimer's agitation • Source: Shutterstock

H. Lundbeck A/S looks well-positioned as it awaits adding an Alzheimer’s disease agitation (AAD) indication to the US label for its atypical antipsychotic Rexulti (brexpiprazole), with strong earnings from full year 2022 fueling preparations.

Lundbeck and its partner Otsuka Pharmaceutical Co. Ltd. are seeking to become the first companies to obtain a US indication for AAD; their supplemental new drug application (sNDA) has a 7 May action date at the US Food and Drug Administration

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.